Insider Profile
Waddick, Christopher James
1
Companies Filed At
1
Open-Market Buys (2yr)
$50K
Buy Value (2yr, open-market)
Dec 30, 2025
Most Recent Trade
4
Credibility
Score
0%
Hit Rate
-20.5%
Avg 90d Return
-11.9%
Median 90d Return
7
Evaluated Trades
-2.2%
Best Trade
-51.8%
Worst Trade
Hit rate and returns are based on 7 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.
Cross-Company Track Record
THIN HISTORY
—
Hit Rate · 90d
-12.6%
Median Alpha · 90d
1
Closed Buys Evaluated
0%
Beat XIU
All-insider base rate: 59% hit rate  · +1.3% mean alpha (n=11504)
size concentrated
Entry: closing price on SEDI filing date (point-in-time). Exit: 90 calendar days later. Alpha vs XIU.TO (iShares TSX 60). Closed trades only. Not investment advice.
Research 1 closed buys with individual return outcomes available on the Research plan.
Date Company Role Nature Dir. Shares Price Value Score
Dec 30, 2025 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 39,692 — — 45
Dec 03, 2025 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 250,000 $1.40 $350K 45
Sep 30, 2025 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 23,900 — — 45
Dec 16, 2024 $CRDL
Cardiol Therapeutics Inc
— Open Market Buy 25,900 $1.92 $50K 45
Jul 10, 2024 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 285,000 — — 45
Dec 30, 2022 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 8,185 — — 45
Dec 30, 2022 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 8,185 — — 45
Sep 30, 2022 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 555,706 $1.41 $784K 45
Sep 30, 2022 $CRDL
Cardiol Therapeutics Inc
— Comp. Grant Buy 555,706 $1.41 $784K 45
Sep 30, 2022 $CRDL
Cardiol Therapeutics Inc
— Expiry Sell 500,000 — — 45
Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Confluence Scores reflect the company's current score, not the score at time of trade.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.